Influenza A Virus Nucleic Acid Detection Kit (Isothermal Amplification)

Certificate

CE

Epidemiology

Influenza virus, a key member of Orthomyxoviridae, poses a severe threat to human health and infects a broad range of hosts. Seasonal epidemics impact roughly 600 million individuals globally each year and result in 250,000 to 500,000 deaths, with influenza A virus being the primary cause of both infection and mortality. Influenza A virus possesses a single-stranded negative-sense RNA genome. Based on surface hemagglutinin (HA) and neuraminidase (NA), HA subtypes are classified into 16 types and NA into 9 types. Among influenza A viruses, the subtypes capable of direct human infection include A H1N1, H3N2, H5N1, H7N1, H7N2, H7N3, H7N7, H7N9, H9N2, and H10N8. Of these, the H1, H3, H5, and H7 subtypes are highly pathogenic, with H1N1, H3N2, H5N7, and H7N9 being particularly noteworthy. The antigenicity of influenza A virus is prone to variation, allowing new subtypes to emerge and trigger global pandemics. Starting in March 2009, a novel H1N1 influenza A outbreak began in Mexico and the United States and subsequently spread worldwide. Influenza A virus can be transmitted through multiple routes, including the digestive and respiratory tracts, damaged skin, and the eyes and conjunctiva. Post-infection symptoms mainly include high fever, cough, runny nose, and myalgia, often accompanied by severe pneumonia. In severe cases, organ failure of the heart, kidneys, and other organs can lead to death, resulting in a high fatality rate. Consequently, there is an urgent clinical need for a simple, accurate, and rapid diagnostic method for influenza A virus to guide medication and diagnosis.

Work Flow

Option 1: The recommended extraction process uses a Viral DNA/RNA Kit paired with an automatic nucleic acid extractor.

Option 2: Alternatively, employ a nucleic acid extraction or purification reagent (YDP302).